Charles River Laboratories International, Inc. (CRL)

Market Cap	8.56B +53.5%
Revenue (ttm)	4.03B +0.1%
Net Income	-184.65M
EPS	-3.76
Shares Out	48.17M
PE Ratio	n/a
Forward PE	15.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	978,194
Open	182.56
Previous Close	181.68
Day's Range	174.07 - 183.65
52-Week Range	132.58 - 228.88
Beta	1.45
Analysts	Buy
Price Target	201.00 (+13.16%)
Earnings Date	May 7, 2026

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 19,700
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Analyst Summary

According to 12 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $201.0, which is an increase of 13.16% from the latest price.

Price Target

$201.0

(13.16% upside)

Analyst Consensus: Buy